{"title":"Avanir获得OptiNose治疗偏头痛的NDA-Ready药物装置组合的北美权利","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I7.1966","DOIUrl":null,"url":null,"abstract":"Avanir Pharmaceuticals has licensed North American rights to OptiNose’s Breath Powered™ intranasal delivery system containing low-dose sumatriptan powder for the treatment of acute migraine. The two companies will collaborate to complete the remaining activities needed to support regulatory submission of the drug-device combination, now known as AVP-825, with NDA filing expected by early 2014. If approved, AVP-825 will diversify Avanir’s CNS product portfolio beyond Nuedexta® (dextromethorphan plus quinidine sulphate), which is indicated for the treatment of pseudobulbar affect.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"19 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Avanir Licenses North American Rights to OptiNose’s NDA-Ready Drug-Device Combination for Migraine\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I7.1966\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Avanir Pharmaceuticals has licensed North American rights to OptiNose’s Breath Powered™ intranasal delivery system containing low-dose sumatriptan powder for the treatment of acute migraine. The two companies will collaborate to complete the remaining activities needed to support regulatory submission of the drug-device combination, now known as AVP-825, with NDA filing expected by early 2014. If approved, AVP-825 will diversify Avanir’s CNS product portfolio beyond Nuedexta® (dextromethorphan plus quinidine sulphate), which is indicated for the treatment of pseudobulbar affect.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"19 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-07-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I7.1966\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I7.1966","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Avanir Licenses North American Rights to OptiNose’s NDA-Ready Drug-Device Combination for Migraine
Avanir Pharmaceuticals has licensed North American rights to OptiNose’s Breath Powered™ intranasal delivery system containing low-dose sumatriptan powder for the treatment of acute migraine. The two companies will collaborate to complete the remaining activities needed to support regulatory submission of the drug-device combination, now known as AVP-825, with NDA filing expected by early 2014. If approved, AVP-825 will diversify Avanir’s CNS product portfolio beyond Nuedexta® (dextromethorphan plus quinidine sulphate), which is indicated for the treatment of pseudobulbar affect.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
